HEALTH● LOWJul 8 · Jul 8, 2026, 2:56 PM
Arcutis gets FDA review for Zoryve 0.05% label expansion
Seeking Alpha Tech
Arcutis has received FDA review for the label expansion of its drug, Zoryve 0.05%, which could lead to broader applications for the medication.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH31m agoWhy the world’s first spinal cord transplant is so controversialNew ScientistHEALTH31m agoFG disburses N249.6bn health fund in three years, targets 17,600 facilitiesPremium TimesHEALTH1h agoChristina Applegate left with health questions after revealing MS misdiagnosisCBS NewsHEALTH1h agoLagos begins mandatory health insurance enforcement January 2027Vanguard Nigeria